Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$1.893M
TTM
Current Assets
Q2 2024
Current Liabilities
Q2 2024
Current Ratio
0.67%
Q2 2024
Total Assets
Q2 2024
Total Liabilities
Q2 2024
Book Value
-$7.425M
Q2 2024
Cash
Q2 2024
P/E
-0.2943
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $665.0K $1.173M $750.6K $1.216M $390.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $10.00K $10.00K $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% -43.3% 56.28% -38.26% 211.7% -100.0% 0.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $665.0K $1.173M $750.6K $1.216M $390.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $10.00K $10.00K $0.00 $0.00 $0.00 $0.00
Cost Of Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $438.7K $791.4K $474.0K $912.4K $280.0K
Gross Profit $0.00 $0.00 $0.00 $0.00 $0.00 $226.3K $381.6K $276.5K $303.2K $110.0K
Gross Profit Margin 34.03% 32.53% 36.84% 24.94% 28.21%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Selling, General & Admin $2.312M $1.182M $2.699M $828.9K $544.7K $428.3K $453.2K $482.8K $520.8K $530.0K $530.0K $730.0K $950.0K $1.470M $3.850M $4.000M $2.090M $2.350M $890.0K $1.400M $150.0K $50.00K
YoY Change 95.71% -56.22% 225.61% 52.17% 27.17% -5.49% -6.12% -7.3% -1.74% 0.0% -27.4% -23.16% -35.37% -61.82% -3.75% 91.39% -11.06% 164.04% -36.43% 833.33% 200.0%
% of Gross Profit 189.25% 118.79% 174.59% 171.75% 481.82%
Research & Development $154.4K $186.1K $146.1K $0.00 $430.0K $120.0K $280.0K $290.0K $440.0K $950.0K $500.0K $130.0K $0.00 $0.00
YoY Change -17.06% 27.4% -100.0% 258.33% -57.14% -3.45% -53.68% 90.0% 284.62%
% of Gross Profit 0.0%
Depreciation & Amortization $580.00 $280.00 $160.00 $1.600K $4.650K $10.00K $30.00K $40.00K $40.00K $90.00K $130.0K $260.0K $80.00K $80.00K $20.00K $0.00 $0.00 $0.00
YoY Change 107.14% 75.0% -90.0% -65.59% -53.5% -66.67% -25.0% 0.0% -55.56% -30.77% -50.0% 225.0% 0.0% 300.0%
% of Gross Profit 0.12% 0.04% 0.58% 1.53% 9.09%
Operating Expenses $2.467M $1.368M $2.699M $828.9K $544.7K $428.6K $453.4K $484.4K $525.5K $540.0K $990.0K $900.0K $1.270M $1.850M $3.980M $4.260M $2.600M $3.380M $1.380M $1.530M $150.0K $50.00K
YoY Change 80.37% -49.33% 225.61% 52.18% 27.08% -5.47% -6.39% -7.82% -2.69% -45.45% 10.0% -29.13% -31.35% -53.52% -6.57% 63.85% -23.08% 144.93% -9.8% 920.0% 200.0%
Operating Profit -$2.467M -$1.368M -$2.699M -$828.9K -$544.7K -$202.3K -$71.85K -$207.9K -$222.2K -$430.0K
YoY Change 80.37% -49.33% 225.61% 52.18% 169.27% 181.54% -65.43% -6.47% -48.32%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Interest Expense $1.223M $1.694M $170.2K -$1.074M $2.137M -$3.533M -$232.0K -$63.64K -$1.134M -$280.0K -$290.0K -$220.0K -$50.00K -$50.00K $0.00 $180.0K $250.0K -$70.00K -$20.00K $0.00 $0.00 $0.00
YoY Change -27.8% 895.33% -115.85% -150.27% -160.49% 1422.85% 264.5% -94.39% 305.05% -3.45% 31.82% 340.0% 0.0% -100.0% -28.0% -457.14% 250.0%
% of Operating Profit
Other Income/Expense, Net -$2.258M -$348.3K $16.22K -$100.00 -$200.00 $16.38K $35.72K $0.00 -$10.00K $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change 548.33% -2247.41% -50.0% -101.22% -54.14% -100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Pretax Income -$4.725M -$1.716M -$2.512M -$6.991M $1.592M -$3.969M -$498.7K -$242.9K -$1.321M -$1.950M -$2.520M -$1.560M -$1.120M -$2.210M -$10.63M -$4.060M -$1.290M -$3.440M -$1.400M -$1.510M -$150.0K -$50.00K
YoY Change 175.35% -31.7% -64.06% -539.16% -140.11% 696.02% 105.32% -81.61% -32.27% -22.62% 61.54% 39.29% -49.32% -79.21% 161.82% 214.73% -62.5% 145.71% -7.28% 906.67% 200.0%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.725M -$1.716M -$2.512M -$6.770M $2.344M -$3.969M -$498.7K -$242.9K -$1.321M -$1.950M -$2.520M -$1.560M -$1.120M -$2.210M -$10.63M -$4.060M -$1.290M -$3.440M -$1.400M -$1.510M -$150.0K -$50.00K
YoY Change 175.35% -31.7% -62.89% -388.83% -159.05% 696.02% 105.32% -81.61% -32.27% -22.62% 61.54% 39.29% -49.32% -79.21% 161.82% 214.73% -62.5% 145.71% -7.28% 906.67% 200.0%
Net Earnings / Revenue -596.89% -42.51% -32.36% -108.64% -500.0% -12900.0% -34400.0%
Basic Earnings Per Share -$0.23 -$0.10 -$0.22
Diluted Earnings Per Share -$0.23 -$0.10 -$223.1K -$4.222M $468.8K -$2.932M -$535.6K -$331.1K -$2.033M -$3.639K -$7.335K -$6.294K -$5.123K -$10.81K -$56.11K -$24.31K -$8.233K -$24.93K -$11.30K -$13.24K -$1.348K -$64.94K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Cash & Short-Term Investments $21.42K $64.25K $180.7K $180.00 $7.960K $41.09K $23.06K $22.17K $78.77K $50.00K $40.00K $40.00K $70.00K $200.0K $530.0K $2.390M $1.770M $4.310M $180.0K $40.00K $0.00 $0.00
YoY Change -66.66% -64.44% 100272.22% -97.74% -80.63% 78.19% 4.01% -71.85% 57.54% 25.0% 0.0% -42.86% -65.0% -62.26% -77.82% 35.03% -58.93% 2294.44% 350.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $40.83K $60.65K $27.47K $0.00 $6.580K $5.400K $6.970K $2.270K $4.170K $10.00K $20.00K $160.0K $10.00K $10.00K $420.0K $1.430M $50.00K $350.0K $80.00K $20.00K
YoY Change -32.68% 120.79% -100.0% 21.85% -22.53% 207.05% -45.56% -58.3% -50.0% -87.5% 1500.0% 0.0% -97.62% -70.63% 2760.0% -85.71% 337.5% 300.0%
Inventory $0.00 $10.13K $6.660K
Prepaid Expenses
Receivables $0.00 $198.1K $106.8K $17.13K $30.80K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $62.25K $124.9K $208.1K $180.00 $212.6K $153.3K $47.15K $65.36K $89.60K $60.00K $50.00K $210.0K $80.00K $220.0K $950.0K $3.820M $1.830M $4.650M $260.0K $60.00K $0.00 $0.00
YoY Change -50.16% -39.99% 115527.78% -99.92% 38.68% 225.17% -27.86% -27.05% 49.33% 20.0% -76.19% 162.5% -63.64% -76.84% -75.13% 108.74% -60.65% 1688.46% 333.33%
Property, Plant & Equipment $0.00 $2.570K $870.00 $1.150K $540.00 $5.270K $10.00K $90.00K $80.00K $40.00K $80.00K $210.0K $280.0K $540.0K $400.0K $170.0K $0.00
YoY Change -100.0% 195.4% -24.35% 112.96% -89.75% -47.3% -88.89% 12.5% 100.0% -50.0% -61.9% -25.0% -48.15% 35.0% 135.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $310.0K $90.00K $230.0K $210.0K $5.830M $10.00K $30.00K $0.00 $0.00
YoY Change -100.0% 244.44% -60.87% 9.52% -96.4% 58200.0% -66.67%
Total Long-Term Assets $0.00 $0.00 $0.00 $0.00 $2.570K $860.00 $1.140K $540.00 $5.270K $10.00K $100.0K $390.0K $120.0K $310.0K $430.0K $6.100M $3.910M $2.230M $180.0K $10.00K $0.00 $0.00
YoY Change -100.0% 198.84% -24.56% 111.11% -89.75% -47.3% -90.0% -74.36% 225.0% -61.29% -27.91% -92.95% 56.01% 75.34% 1138.89% 1700.0%
Total Assets $62.25K $124.9K $208.1K $180.00 $215.2K $154.2K $48.29K $65.90K $94.87K $70.00K $150.0K $600.0K $200.0K $530.0K $1.380M $9.920M $5.740M $6.880M $440.0K $70.00K $0.00 $0.00
YoY Change
Accounts Payable $514.7K $375.7K $143.1K $88.52K $129.4K $134.4K $83.87K $46.52K $41.92K $130.0K $150.0K $140.0K $170.0K $420.0K $390.0K $430.0K $260.0K $580.0K $80.00K $90.00K $0.00 $200.0K
YoY Change 37.0% 162.58% 61.62% -31.61% -3.7% 60.25% 80.29% 10.97% -67.75% -13.33% 7.14% -17.65% -59.52% 7.69% -9.3% 65.38% -55.17% 625.0% -11.11% -100.0%
Accrued Expenses $304.1K $103.4K $367.4K $65.22K $54.48K $55.76K $39.21K $28.85K $25.87K $40.00K $20.00K $40.00K $100.0K $60.00K $20.00K $30.00K $50.00K $10.00K $50.00K $10.00K $0.00 $20.00K
YoY Change 194.24% -71.87% 463.32% 19.71% -2.3% 42.21% 35.91% 11.52% -35.33% 100.0% -50.0% -60.0% 66.67% 200.0% -33.33% -40.0% 400.0% -80.0% 400.0% -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $33.50K $22.87K $12.00K $36.29K $19.20K $43.50K $43.50K $47.00K $227.4K $250.0K $70.00K $410.0K $460.0K $460.0K $0.00 $0.00 $0.00 $0.00 $850.0K $0.00 $0.00 $200.0K
YoY Change 46.48% 90.58% -66.93% 89.01% -55.86% 0.0% -7.45% -79.33% -9.03% 257.14% -82.93% -10.87% 0.0% -100.0% -100.0%
Long-Term Debt Due $2.166M $1.267M $129.7K $91.70K $36.22K $31.74K $92.17K $131.9K
YoY Change 71.03% 876.89% 41.4% 153.18% 14.11% -65.56% -30.12%
Total Short-Term Liabilities $7.861M $4.778M $3.970M $3.455M $2.285M $4.626M $966.9K $791.4K $974.1K $970.0K $940.0K $750.0K $730.0K $940.0K $430.0K $500.0K $310.0K $590.0K $970.0K $100.0K $0.00 $420.0K
YoY Change 64.52% 20.34% 14.92% 51.18% -50.6% 378.45% 22.18% -18.76% 0.42% 3.19% 25.33% 2.74% -22.34% 118.6% -14.0% 61.29% -47.46% -39.18% 870.0% -100.0%
Long-Term Debt $0.00 $0.00 $165.9K $115.0K $165.9K $165.9K $125.7K $115.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $460.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% 44.24% -30.67% 0.01% 32.01% 9.26% -100.0%
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $165.9K $115.0K $165.9K $165.9K $125.7K $115.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $460.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% 44.24% -30.67% 0.01% 32.01% 9.26% -100.0%
Total Liabilities $7.861M $4.778M $4.136M $3.570M $2.451M $4.792M $1.093M $906.4K $974.1K $970.0K $940.0K $750.0K $730.0K $940.0K $890.0K $500.0K $310.0K $590.0K $970.0K $100.0K $0.00 $420.0K
YoY Change 64.52% 15.52% 15.86% 45.64% -48.85% 338.61% 20.54% -6.96% 0.42% 3.19% 25.33% 2.74% -22.34% 5.62% 78.0% 61.29% -47.46% -39.18% 870.0% -100.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Basic Shares Outstanding 20.83M shares 16.53M shares 11.26M shares
Diluted Shares Outstanding 20.83M shares 16.53M shares 11.26M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $557.16 Thousand

About NovAccess Global Inc.

NovAccess Global, Inc. is a biopharmaceutical company, which engages in the provision of diagnostics, therapeutics in cancer, and neurological diseases and the development of immunotherapies to treat brain tumor patients. The company is headquartered in Chagrin Falls, Ohio and currently employs 1 full-time employees. The company went IPO on 2002-05-01. The firm specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

Industry: Pharmaceutical Preparations Peers: ACTAVIA LIFE SCIENCES, INC. Allena Pharmaceuticals, Inc. Qrons Inc. International Stem Cell CORP Histogen Inc.